EVOK has 36-month beta value of 0.38. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EVOK is 0.74M, and currently, short sellers hold a 10.46% ratio of that float. The average trading volume of EVOK on September 24, 2024 was 61.55K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
EVOK) stock’s latest price update
Evoke Pharma Inc (NASDAQ: EVOK) has experienced a rise in its stock price by 16.63 compared to its previous closing price of 4.51. However, the company has seen a gain of 24.62% in its stock price over the last five trading days. globenewswire.com reported 2024-09-19 that Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis
EVOK’s Market Performance
EVOK’s stock has risen by 24.62% in the past week, with a monthly rise of 18.74% and a quarterly drop of -21.87%. The volatility ratio for the week is 11.66% while the volatility levels for the last 30 days are 8.98% for Evoke Pharma Inc The simple moving average for the past 20 days is 23.73% for EVOK’s stock, with a -27.93% simple moving average for the past 200 days.
Analysts’ Opinion of EVOK
Many brokerage firms have already submitted their reports for EVOK stocks, with H.C. Wainwright repeating the rating for EVOK by listing it as a “Buy.” The predicted price for EVOK in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on June 22, 2020 of the previous year 2020.
B. Riley FBR Inc. gave a rating of “Buy” to EVOK, setting the target price at $5 in the report published on March 08th of the previous year.
EVOK Trading at 2.71% from the 50-Day Moving Average
After a stumble in the market that brought EVOK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.72% of loss for the given period.
Volatility was left at 8.98%, however, over the last 30 days, the volatility rate increased by 11.66%, as shares surge +19.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.37% lower at present.
During the last 5 trading sessions, EVOK rose by +24.62%, which changed the moving average for the period of 200-days by -67.77% in comparison to the 20-day moving average, which settled at $4.29. In addition, Evoke Pharma Inc saw -58.27% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for EVOK
Current profitability levels for the company are sitting at:
- -0.83 for the present operating margin
- 0.97 for the gross margin
The net margin for Evoke Pharma Inc stands at -0.87. The total capital return value is set at -2.33. Equity return is now at value -407.60, with -61.83 for asset returns.
Based on Evoke Pharma Inc (EVOK), the company’s capital structure generated 0.65 points at debt to capital in total, while cash flow to debt ratio is standing at -1.11. The debt to equity ratio resting at 1.88. The interest coverage ratio of the stock is -12.4.
Currently, EBITDA for the company is -7.43 million with net debt to EBITDA at 0.68. When we switch over and look at the enterprise to sales, we see a ratio of 0.02. The receivables turnover for the company is 3.76for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.28.
Conclusion
To put it simply, Evoke Pharma Inc (EVOK) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
